Seeking Alpha

Inovio Pharmaceuticals: Neutral On INO-3107 Amidst Stock Dilution And High Valuation

Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...
Nasdaq

Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients ...

PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
Seeking Alpha

FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
Benzinga.com

DNA Medicine Focused INOVIO Pharma Efficiencies Implemented By Leadership Will Help De-Risk Its Platform Technology: Analyst

Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO), noting the company’s diversified clinical pipeline of therapeutic and vaccine candidates, which the company is looking to ...
Hosted on MSN

INOVIO to Showcase Breakthrough Data on INO-3107 at Major Industry Conferences

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced its participation in several prominent conferences, where it will present significant findings related to its lead candidate, INO-3107. The ...